Key Points
- Director David Weill purchased 1,336 TransMedics shares for approximately $109,058, increasing his position by 8.87% to 16,392 shares.
- TransMedics reported quarterly revenue of $189.95 million, exceeding estimates, while EPS of $0.44 fell short of the $0.50 consensus; revenue rose 20.7% year over year.
- Institutional investors own 99.67% of the stock, while analysts maintain a consensus “Hold” rating with an average price target of $124.18.
TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director David Weill purchased 1,336 shares of the stock in a transaction on Friday, September 11th. The shares were purchased at an average price of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
TransMedics Group Price Performance
TMDX stock opened at $85.86 on Tuesday. The company's 50-day moving average is $82.29 and its 200-day moving average is $89.90. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The stock has a market capitalization of $2.97 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 1.13 and a beta of 1.90.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million for the quarter, compared to analysts' expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group's revenue was up 20.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.92 earnings per share. Equities research analysts expect that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.
Institutional Trading of TransMedics Group
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. WINTON GROUP Ltd boosted its holdings in shares of TransMedics Group by 52.4% in the 2nd quarter. WINTON GROUP Ltd now owns 18,203 shares of the company's stock valued at $1,209,000 after buying an additional 6,262 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in shares of TransMedics Group by 31.3% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 2,877 shares of the company's stock worth $191,000 after purchasing an additional 686 shares during the period. IFP Advisors Inc boosted its position in TransMedics Group by 4.8% during the second quarter. IFP Advisors Inc now owns 4,652 shares of the company's stock worth $309,000 after purchasing an additional 213 shares in the last quarter. Corient Private Wealth LP increased its position in shares of TransMedics Group by 123.2% in the second quarter. Corient Private Wealth LP now owns 19,285 shares of the company's stock valued at $1,281,000 after buying an additional 10,644 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of TransMedics Group during the 2nd quarter worth approximately $551,000. Institutional investors own 99.67% of the company's stock.
Analysts Set New Price Targets
TMDX has been the subject of several research analyst reports. UBS Group dropped their price target on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating for the company in a research note on Wednesday, August 5th. Needham & Company LLC reiterated a "buy" rating on shares of TransMedics Group in a research note on Friday. Stifel Nicolaus boosted their price target on TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, June 18th. Weiss Ratings raised TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. Finally, Canaccord Genuity Group restated a "buy" rating and set a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $124.18.
Read Our Latest Stock Analysis on TransMedics Group
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.
Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
